Does Wegovy melt fat, or does something else explain the weight loss?

The 'melting fat' idea: where it comes from and why it misses the point

The phrase turns up constantly on social media, usually alongside before-and-after images and the implication that semaglutide acts like a biological solvent on stored fat. It is an appealing shorthand, but if you want to understand whether Wegovy actually helps burn fat and how that process really works, the distinction matters when you are deciding whether it is right for you.

Fat stored in adipose tissue does not get dissolved, broken down chemically by the drug, or flushed out. What Wegovy does is act on the hormonal conversation between your gut, your brain, and your appetite. Semaglutide is a GLP-1 receptor agonist: it binds to receptors that respond to the gut hormone GLP-1, which normally rises after eating to signal fullness and slow the rate at which your stomach empties. The NHS medicines page for semaglutide describes this mechanism clearly and is worth reading before you start.

The practical result for most people is that food feels filling much sooner, cravings quiet down, and the default urge to eat between meals fades. None of that burns fat directly. What it does is make a sustained calorie deficit far more achievable than willpower alone could manage. The deficit is what prompts the body to draw on its stored energy reserves. Fat loss follows from that, steadily, over months. It is biology rather than chemistry, and understanding that helps set realistic expectations about pace and effort.

What the trial evidence says about body composition (and what it does not say

The STEP 1 trial) 1,961 adults with obesity, 68 weeks, semaglutide 2.4 mg versus placebo, found an average body-weight reduction of around 15% in the treatment group. That translates to roughly 15 kg for someone starting at 100 kg. Most of that loss is fat mass, though some muscle loss is also documented, which is one reason prescribers emphasise protein intake and resistance exercise alongside treatment.

The MHRA approved a higher 7.2 mg maintenance dose in January 2026, with a dedicated single-dose pen confirmed in April 2026. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide. If you are curious how the two medicines compare, the detail on Wegovy's fat-loss evidence covers that ground properly.

One thing the trials do not tell us is where on the body fat is lost preferentially. Visceral fat (the metabolically active fat around the organs) does reduce with significant overall weight loss, and there is good evidence that reducing it lowers cardiovascular risk. But Wegovy cannot target your abdomen, hips, or anywhere else specifically. Whether Wegovy helps with belly fat in particular is a question worth exploring separately, because the answer is nuanced.

The practical factors that shape your actual result

The decision most people are really making when they ask this question is not a scientific one. It is: will this work well enough for me, and is it the right approach for my situation?

Three things shape individual results more than the mechanism does. First, adherence: the medicine works while you take it; weight tends to return when you stop, because the hormonal signal stops too. Second, what you eat: Wegovy dramatically reduces how much you want to eat, but it does not override a consistently poor diet indefinitely. Protein, hydration and fibre matter. Third, your starting point: people with a higher BMI and certain comorbidities tend to see larger absolute reductions, which is part of why the licensed eligibility criteria for Wegovy exist.

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. A prescriber weighs all of this at the consultation stage, it is not simply a BMI threshold you either clear or you do not.

Worth knowing: treatment is once weekly by subcutaneous injection, starting at 0.25 mg and increasing slowly under prescriber guidance to the maintenance dose. The dose ladder exists to reduce the GI side effects that catch people off-guard in the first few weeks. Nausea is common early on, particularly after a dose increase, and usually settles. A full side-effect picture is on the Wegovy patient information page.

Getting started: what the process actually looks like

If you are weighing up whether to begin, the overview of weight-loss treatment options at nume is a useful starting point. For people who decide to go ahead through a private, clinician-led route, the process is straightforward: a free online consultation is read and assessed the same day by a GPhC-registered independent prescriber, a real clinician, not software. If the treatment is clinically appropriate, the prescription is issued, and the medicine is dispatched the same day for free next-working-day DPD delivery in plain, unbranded packaging.

There is no subscription. Every repeat order is clinically re-reviewed. For a sense of what private treatment costs and what an honest price includes, the Wegovy price comparison guide covers that without any sales pressure.

If you would like to explore whether Wegovy is right for your circumstances, check your eligibility with a free consultation, the clinical team can answer questions the internet cannot.